Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

'Barrier dysfunction in Atopic newBorns studY' (BABY): protocol of a Danish prospective birth cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Gerner, Trine ; Halling, Anne-Sofie ; Rasmussen Rinnov, Maria ; Haarup Ravn, Nina ; Hjorslev Knudgaard, Mette ; Menné Bonefeld, Charlotte ; Ewertsen, Caroline ; Trautner, Simon ; Jakaša, Ivone ; Kezic, Sanja ; Skov, Lone ; Thyssen, Jacob P. / 'Barrier dysfunction in Atopic newBorns studY' (BABY) : protocol of a Danish prospective birth cohort study. I: BMJ Open. 2020 ; Bind 10, Nr. 7. s. e033801.

Bibtex

@article{d3152649ab53497cafdf969e07692e15,
title = "'Barrier dysfunction in Atopic newBorns studY' (BABY): protocol of a Danish prospective birth cohort study",
abstract = "INTRODUCTION: Skin barrier development and dysfunction in premature and mature newborns is important for the risk of atopic dermatitis (AD).METHODS AND ANALYSIS: The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a prospective birth cohort study of 150 preterm children (gestational age (GA) below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed through transepidermal water loss, tape stripping, Raman-spectroscopy and microbiome sampling. Clinical examinations are done and DNA from buccal swabs is collected for genetic analyses. Thymus size is assessed by ultrasound examination. Information on pregnancy, delivery, parental exposures and diseases are collected, and structured telephone interviews are conducted at 18 and 24 months to assess exogenous exposures in the child and onset of AD. Hanifin and Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM).ETHICS AND DISSEMINATION: The study is approved by the scientific Ethical Committee of the Capital Region (H-16042289 and H-16042294).Outcomes will be presented at national and international conferences and in peer-reviewed publications.",
author = "Trine Gerner and Anne-Sofie Halling and {Rasmussen Rinnov}, Maria and {Haarup Ravn}, Nina and {Hjorslev Knudgaard}, Mette and {Menn{\'e} Bonefeld}, Charlotte and Caroline Ewertsen and Simon Trautner and Ivone Jakaša and Sanja Kezic and Lone Skov and Thyssen, {Jacob P}",
note = "{\circledC} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = "7",
day = "12",
doi = "10.1136/bmjopen-2019-033801",
language = "English",
volume = "10",
pages = "e033801",
journal = "BMJ Paediatrics Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - 'Barrier dysfunction in Atopic newBorns studY' (BABY)

T2 - protocol of a Danish prospective birth cohort study

AU - Gerner, Trine

AU - Halling, Anne-Sofie

AU - Rasmussen Rinnov, Maria

AU - Haarup Ravn, Nina

AU - Hjorslev Knudgaard, Mette

AU - Menné Bonefeld, Charlotte

AU - Ewertsen, Caroline

AU - Trautner, Simon

AU - Jakaša, Ivone

AU - Kezic, Sanja

AU - Skov, Lone

AU - Thyssen, Jacob P

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/7/12

Y1 - 2020/7/12

N2 - INTRODUCTION: Skin barrier development and dysfunction in premature and mature newborns is important for the risk of atopic dermatitis (AD).METHODS AND ANALYSIS: The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a prospective birth cohort study of 150 preterm children (gestational age (GA) below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed through transepidermal water loss, tape stripping, Raman-spectroscopy and microbiome sampling. Clinical examinations are done and DNA from buccal swabs is collected for genetic analyses. Thymus size is assessed by ultrasound examination. Information on pregnancy, delivery, parental exposures and diseases are collected, and structured telephone interviews are conducted at 18 and 24 months to assess exogenous exposures in the child and onset of AD. Hanifin and Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM).ETHICS AND DISSEMINATION: The study is approved by the scientific Ethical Committee of the Capital Region (H-16042289 and H-16042294).Outcomes will be presented at national and international conferences and in peer-reviewed publications.

AB - INTRODUCTION: Skin barrier development and dysfunction in premature and mature newborns is important for the risk of atopic dermatitis (AD).METHODS AND ANALYSIS: The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a prospective birth cohort study of 150 preterm children (gestational age (GA) below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed through transepidermal water loss, tape stripping, Raman-spectroscopy and microbiome sampling. Clinical examinations are done and DNA from buccal swabs is collected for genetic analyses. Thymus size is assessed by ultrasound examination. Information on pregnancy, delivery, parental exposures and diseases are collected, and structured telephone interviews are conducted at 18 and 24 months to assess exogenous exposures in the child and onset of AD. Hanifin and Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM).ETHICS AND DISSEMINATION: The study is approved by the scientific Ethical Committee of the Capital Region (H-16042289 and H-16042294).Outcomes will be presented at national and international conferences and in peer-reviewed publications.

U2 - 10.1136/bmjopen-2019-033801

DO - 10.1136/bmjopen-2019-033801

M3 - Journal article

VL - 10

SP - e033801

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2044-6055

IS - 7

ER -

ID: 60481006